What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

The rest of Europe could learn from them. Politicians in Brussels are perpetually searching for ways to invigorate the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, ...

Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking ...

Explore 13 of the most technologically advanced countries leading in innovation, research, and technological development ...

The proposed Biosecure Act as well as the diversification of American and European firms away from China are expected to help ...

Novo Nordisk has acquired UK start-up Ziylo in a deal worth up to $800m in a bid to develop the world’s first “smart” insulin, capable of modulating its effectiveness depending on how much ...